Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 740 participants.
Also called NCT02173457
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 740 participants
- Sponsor
- Registry
-
NCT02173457
-
- Other papers using this trial's data
- Comparative Evaluation of Chiglitazar and Sitagliptin on the Levels of Retinol-Binding Protein 4 and Its Correlation With Insulin Resistance in Patients With Type 2 Diabetes
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02173457. Randomized; double masking; primary purpose treatment. Start 2014-09 (actual); primary completion 2017-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients
- Acronym
- CMAS
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Chiglitazar
- Intervention (Drug)
- Sitagliptin
- Lead sponsor
- Chipscreen Biosciences, Ltd.
Record details
- Record id
cardio:ct-nct02173457- Content hash
fdeb3dfbc0caebacfebb74c9cb160087c5943f21b23eff6c287ac1062898746f